MaxCyte CEO Says FDA OK Of IND For Its CAR Receptor Candidate Major Milestone

 
• By Sten Stovall
  
CART
IND Means First CARMA Trial Is On Track For Dosing In Second Half 2018 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D